Pasireotide LA is under clinical development by Recordati and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pasireotide LA’s likelihood of approval (LoA) and phase transition for Lung Cancer took place on 27 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 27 Nov 2020 decreased Pasireotide LA’s LoA and PTSR for Thymic Carcinoma.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pasireotide LA Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pasireotide LA overview

Pasireotide (Signifor LAR/ Signifor LP) is a synthetic long-acting cyclic hexapeptide somatostatin analogue. It is formulated extended release powder for suspension for intramuscular route of administration for long acting release. It is indicated to treat adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA) and for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option
or has not been curative.

Pasireotide LAR is under development for the treatment of neuroendocrine carcinoma of the lung and thymus.

It was also under development of hormone refractory (castration resistant, androgen-independent) prostate cancer as first line and second line therapy, neuroendocrine gastro-entero-pancreatic tumors, Nelson syndrome, relapsed/refractory multiple myeloma, carcinoid tumor, relapsed or refractory small cell lung cancer, pancreatic cancer, Merkel cell carcinoma, metastatic melanoma, gastrointestinal malignancies including colon cancer, gastric cancer, esophageal cancer, graves’ ophthalmopathy, pituitary tumor, uveal melanoma and meningiomas.

Recordati overview

Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.

Quick View Pasireotide LA LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Pasireotide LA
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Hormonal Disorders
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
Key Developers
  • Sponsor Company: Recordati
  • Originator: Novartis
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.